ImmunoGen Wins New Chance To Receive Patent on Ovarian Cancer Treatment

“A U.S. appeals court on Friday revived a lawsuit brought by biotech company ImmunoGen Inc in an attempt to secure a patent related to its planned ovarian cancer treatment.

ImmunoGen should get another chance to convince a Virginia federal court that it was entitled to the patent, a U.S. Court of Appeals for the Federal Circuit panel said, finding a lower-court judge analyzed the company’s application incorrectly when he ruled the patent, related to a specific dosage of the drug, was not patent eligible.”

Director Michael Joffre, Ph.D., was mentioned as ImmunoGen’s representation in the article “ImmunoGen Wins New Chance To Receive Patent on Ovarian Cancer Treatment,” published by Reuters. The team also included Directors Pauline M. Pelletier and Eric K. Steffe.